Reported 2 days ago
Vertex Pharmaceuticals anticipates strong revenue for 2025, driven by increased sales of its cystic fibrosis drugs and the launch of a new non-opioid painkiller, Journavx. The company expects to begin shipments of Journavx by the end of February. With its newly approved treatment Alyftrek and a promising sales record of its existing drug Trikafta, Vertex is poised for continued growth, forecasting revenues of $11.75 billion to $12.0 billion, surpassing analyst expectations.
Source: YAHOO